InsuLine begins insulin patch FDA trial

InsuLine expects that if the trial succeeds, the company will gain FDA approval by the end of 2011.

InsuLine Medical Ltd. (TASE: INSL) has begun a clinical trial in the US to test the safety and effectiveness of its InsuPatch catheter for insulin pumps on type 1 diabetics. The trial is based on US Food and Drug Administration (FDA) protocols, and the company plans to shortly begin a corresponding trial in Israel based on the same protocols.

The trial will include 100 patients in Israel and the US, and the company believes that it will be completed in the third quarter of 2011. The trial will be conducted in two parallel parts: in the first part, 15 patients will test the InsuPatch's effectiveness in a controlled environment; and in the second part, 15 patients will test its safety in an uncontrolled day-to-day life environment.

The US trial will be conducted at the Mills Peninsula Health Center in California.

The InsuPatch is intended to enable faster insulin absorption.

InsuLine president and CEO Ron Nagar said, "The start of the clinical trial in accordance with FDA protocols is a critical milestone in the company's life, and follows previous clinical trials conducted by InsuLine, which have demonstrated the effectiveness and safety of the product."

InsuLine expects that if the trial succeeds, the company will gain US Food and Drug Administration (FDA) approval by the end of 2011.

InsuLine's share price rose 2.1% by early afternoon to NIS 0.79, giving a market cap of NIS 41 million.

Published by Globes [online], Israel business news - www.globes-online.com - on October 27, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס